With late-stage da­ta in on the CGRP mi­graine drug erenum­ab, No­var­tis and Am­gen re­work com­mer­cial­iza­tion pact

Five months af­ter Am­gen and No­var­tis out­lined their sec­ond batch of pos­i­tive Phase III da­ta for their CGRP mi­graine drug erenum­ab, the two gi­ants have re­worked their com­mer­cial part­ner­ship to give No­var­tis a piece of the US mar­ket — for a price.

Un­der their orig­i­nal deal Am­gen was left in charge of the US, but now No­var­tis has agreed to cov­er part of the com­mer­cial­iza­tion costs in ex­change for a slice of the rev­enue in the all-im­por­tant mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.